Text Size

Magnetic Resonance Imaging and Spectroscopy of the Prostate

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT00590993
First received: December 26, 2007
Last updated: February 27, 2013
Last verified: February 2013
History of Changes
  Purpose

Past studies have shown that MRI is useful for staging prostate cancer. This study will use magnetic resonance spectroscopic imaging (MRSI) to obtain more information. MRSIs with MRIs help doctors locate prostate cancer and determine the extent of tumor before deciding on treatment. This study looks at structural and chemical properties of prostates in prostate cancer patients before and after treatment.


Condition Intervention
Prostate Cancer
 Other: MRI and MRSI

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Magnetic Resonance Imaging and Spectroscopy of the Prostate

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Memorial Sloan-Kettering Cancer Center:

Primary Outcome Measures:
  • Determine added value in combining MRSI and MRI in prostate cancer treatment [ Time Frame: 3 hours ] [ Designated as safety issue: No ]

Enrollment: 1005
Study Start Date: December 2000
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
1 - MRSI / MRI Other: MRI and MRSI
Compare treatment impact when using MRI and MRSI

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Urology and Radiology prostate cancer patients seen at Memorial Sloan-Kettering Cancer Center

Criteria

Inclusion Criteria:

  • prostate cancer patients willing to undergo a MRI and MRSI exam

Exclusion Criteria:

  • patients with prostate cancer and bone or lymph node metastasis
  • patients who can not have an MRI exam
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00590993

Locations
United States, New York
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Investigators
Principal Investigator: Hedvig Hricak, MD Memorial Sloan-Kettering Cancer Center
  More Information

Additional Information:
Memorial Sloan-Kettering Cancer Center  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier: NCT00590993     History of Changes
Other Study ID Numbers: 00-136
Study First Received: December 26, 2007
Last Updated: February 27, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Memorial Sloan-Kettering Cancer Center:
MRSI
MRI
Prostate Cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
 Neoplasms
Genital Diseases, Male
Prostatic Diseases

ClinicalTrials.gov processed this record on May 23, 2013